Entera Bio LTD 8-K filings

Entera Bio Ltd. announced a $275 million private placement and positive FDA feedback for its oral osteoporosis drug EB613, positioning it for Phase 3 trials and NDA submission.

Entera Bio Ltd. announced a $275 million private placement of ordinary shares and pre-funded warrants to institutional and accredited investors, including funds affiliated with BVF Partners L.P.

Entera Bio Ltd. shareholders approved an increase in authorized shares and an amendment to the equity incentive plan at the 2026 Annual Meeting.

Entera Bio Ltd. announced a $10 million private placement of units, comprising ordinary shares and warrants, to funds affiliated with BVF Partners LP.

Entera Bio announced its full year 2025 financial results and provided key business updates, highlighting progress in its oral peptide development programs, particularly EB613 for osteoporosis.

Entera Bio submitted a streamlined Phase 3 protocol to the FDA for its oral osteoporosis treatment, EB613, anticipating topline data by late 2028, approximately one year earlier than expected.

Entera Bio Ltd. announced the appointment of Geno J. Germano, a seasoned pharmaceutical executive, as its new Chairman of the Board, effective February 4, 2026.

Entera Bio and OPKO Health expanded their collaboration to include a long-acting oral PTH tablet for hypoparathyroidism and appointed Steven D. Rubin to Entera's board.

Entera Bio Ltd. announced its third quarter 2025 financial results and provided key business updates, highlighting FDA agreement on EB613's Phase 3 primary endpoint and progress across its oral peptide pipeline.

Entera Bio announced Q2 2025 financial results and a pivotal FDA agreement on the Phase 3 design for its oral osteoporosis treatment, EB613, confirming Bone Mineral Density as the primary endpoint.

Entera Bio announced FDA agreement to use Bone Mineral Density (BMD) as the primary endpoint for its pivotal Phase 3 study of EB613, an oral treatment for post-menopausal osteoporosis, marking a significant regulatory shift.

Entera Bio Ltd. announced that its shareholders approved all seven proposals, including director election and executive compensation, at the 2025 Annual Meeting held on July 16, 2025.

Entera Bio reported its Q1 2025 financial results and business updates, showcasing advancements in its oral peptide and protein replacement therapies, including EB613 for osteoporosis and a collaboration with OPKO Health.

Entera Bio reports its full year 2024 financial results, highlighting key data read-outs and advancements in its oral peptide programs.

Entera Bio and OPKO Health have entered into a collaboration and license agreement to develop an oral GLP-1/glucagon dual agonist tablet for treating obesity and metabolic disorders.

Entera Bio Ltd. files an opinion regarding the issuance of up to 30,000,000 ordinary shares under its at-the-market (ATM) offering program.

Entera Bio Ltd. has amended its previous 8-K filing to clarify the board's decision to hold annual shareholder advisory votes on executive compensation.

Entera Bio announced its Q3 2024 financial results and provided updates on its clinical programs, including its lead candidate EB613 for osteoporosis.

Entera Bio reported its Q2 2024 financial results and provided key business updates, highlighting progress in its oral peptide programs and upcoming milestones.

Entera Bio Ltd. held its 2024 Annual Meeting of Shareholders on July 31, 2024, with all proposals being approved by shareholders.

Entera Bio announced its Q1 2024 financial results, highlighting progress in its oral peptide therapeutic pipeline and a cash runway into Q3 2025.

Entera Bio announced its 2023 financial results and provided updates on its oral peptide development programs, highlighting progress towards clinical trials and regulatory milestones.

Entera Bio has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.

Entera Bio has filed a registration statement with the SEC to allow the resale of ordinary shares and warrants issued in a prior private placement.